GSK plc will acquire Canada-based 35Pharma for $950 million, adding HS235, a phase I-ready drug candidate for pulmonary hypertension, to strengthen its growing cardiopulmonary pipeline.
Zydus Lifesciences is preparing a day-one launch of its semaglutide generic in India after patent expiry in March 2026. The drug will be sold as Semaglyn, Mashema, and Altreme with a reusable multi-dose pen.
.png "Lupin Secures FDA Approval for Brivaracetam Oral Solution")
Lupin Limited has announced FDA approval for its Brivaracetam Oral Solution 10 mg/mL, a bioequivalent of UCB’s Briviact, designed to treat partial-onset seizures in patients 1 month and older. The launch is now underway in the U.S.
Gilead Sciences is acquiring Arcellx in a deal valued at up to $7.8 billion, gaining full control of its CAR-T therapy candidate for multiple myeloma and strengthening its oncology pipeline.
Shilpa Medicare has signed a strategic licensing agreement with SteinCares to commercialize a biosimilar across Latin America, strengthening its biologics portfolio and expanding its presence in emerging markets.
Alembic Pharmaceuticals has secured final approval from the FDA for its efinaconazole topical solution, a treatment for toenail fungal infections. This approval strengthens the company’s growing portfolio in the US market.
Boehringer Ingelheim India has signed a landmark MoU with NIPER Raebareli to advance pharmaceutical innovation, strengthen research in novel drug delivery systems, and support academic collaboration in India’s evolving healthcare ecosystem.
.jpeg "Gleneagles Hospital Launches Renal Denervation Centre in Mumbai")
Gleneagles Hospital, Mumbai, partners with Medtronic India to launch a Renal Denervation Therapy Centre, offering advanced treatment for resistant hypertension and improving outcomes.
.jpeg "Indoco Remedies Gets US FDA Approval for Brivaracetam Oral Solution")
Indoco Remedies gets US FDA approval for its generic brivaracetam oral solution, 10 mg/mL, treating partial-onset seizures. Manufactured in Goa, it's a milestone for the company.
Eris Lifesciences has partnered with Natco Pharma to commercialize semaglutide in India, ahead of the patent expiry of the blockbuster diabetes and weight-loss drug ingredient. The launch is expected in March 2026.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")